Found: 40
Select item for more details and to access through your institution.
Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
- Published in:
- BJU International, 2022, v. 130, n. 1, p. 68, doi. 10.1111/bju.15625
- By:
- Publication type:
- Article
Long-Term Survival in Patients With Advanced Melanoma.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 8, p. e2426641, doi. 10.1001/jamanetworkopen.2024.26641
- By:
- Publication type:
- Article
Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 20, p. 11199, doi. 10.3390/ijms222011199
- By:
- Publication type:
- Article
ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Published in:
- 2023
- By:
- Publication type:
- Abstract
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2023, v. 30, n. 1, p. 573, doi. 10.1245/s10434-022-12600-2
- By:
- Publication type:
- Article
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 10, p. 2086, doi. 10.1002/1878-0261.13196
- By:
- Publication type:
- Article
Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 9, p. 1673, doi. 10.1002/cncr.35178
- By:
- Publication type:
- Article
Platinum exposure and cause‐specific mortality among patients with testicular cancer.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 3, p. 628, doi. 10.1002/cncr.32538
- By:
- Publication type:
- Article
Platinum exposure and cause-specific mortality among patients with testicular cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45714-0
- By:
- Publication type:
- Article
Neuropsychological test performance and self-reported cognitive functioning associated with work-related outcomes in occupationally active cancer survivors with cognitive complaints.
- Published in:
- Journal of Cancer Survivorship, 2024, v. 18, n. 2, p. 412, doi. 10.1007/s11764-022-01223-x
- By:
- Publication type:
- Article
Cancer-related cognitive problems at work: experiences of survivors and professionals.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 3, p. 759, doi. 10.1007/s00262-022-03250-0
- By:
- Publication type:
- Article
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 11, p. 3123, doi. 10.1007/s00262-021-02871-1
- By:
- Publication type:
- Article
Internet-based cognitive rehabilitation for working cancer survivors: results of a multicenter randomized controlled trial.
- Published in:
- JNCI Cancer Spectrum, 2024, v. 8, n. 1, p. 1, doi. 10.1093/jncics/pkad110
- By:
- Publication type:
- Article
Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.
- Published in:
- Cancers, 2024, v. 16, n. 15, p. 2656, doi. 10.3390/cancers16152656
- By:
- Publication type:
- Article
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2922, doi. 10.3390/cancers15112922
- By:
- Publication type:
- Article
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 409, doi. 10.3390/cancers15020409
- By:
- Publication type:
- Article
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.
- Published in:
- Cancers, 2021, v. 13, n. 20, p. 5077, doi. 10.3390/cancers13205077
- By:
- Publication type:
- Article
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4639, doi. 10.3390/cancers13184639
- By:
- Publication type:
- Article
Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2826, doi. 10.3390/cancers13112826
- By:
- Publication type:
- Article
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.
- Published in:
- Cancers, 2020, v. 12, n. 5, p. 1176, doi. 10.3390/cancers12051176
- By:
- Publication type:
- Article
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 1003, doi. 10.3390/cancers12041003
- By:
- Publication type:
- Article
Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma.
- Published in:
- Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v102.980
- By:
- Publication type:
- Article
Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.
- Published in:
- International Journal of Cancer, 2024, v. 155, n. 8, p. 1455, doi. 10.1002/ijc.35060
- By:
- Publication type:
- Article
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 10, p. 1760, doi. 10.1002/ijc.34853
- By:
- Publication type:
- Article
Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 2, p. 389, doi. 10.1002/ijc.34485
- By:
- Publication type:
- Article
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 12, p. 2493, doi. 10.1002/ijc.34479
- By:
- Publication type:
- Article
The unfavorable effects of COVID‐19 on Dutch advanced melanoma care.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 5, p. 816, doi. 10.1002/ijc.33833
- By:
- Publication type:
- Article
Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 2, p. 317, doi. 10.1002/ijc.33800
- By:
- Publication type:
- Article
Real‐world outcomes of advanced melanoma patients not represented in phase III trials.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 12, p. 3461, doi. 10.1002/ijc.33162
- By:
- Publication type:
- Article
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-61150-y
- By:
- Publication type:
- Article